Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-07-21 00:00:00 ET · period of report 2023-07-20 · accession 0001209191-23-043135 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-07-21 | 2023-07-20 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 915.8K | -1% | $0 |
| D | 2023-07-21 | 2023-07-20 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 925.8K | +1% | $0 |
| D | 2023-07-21 | 2023-07-20 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | -10.0K | 6.53M | -0.2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-07-20 | G | D | 10,000 | $0.00 | 915,810 | D | — | — | |
| 2 | Common | Class A Common Stock | 2023-07-20 | C | A | 10,000 | $0.00 | 925,810 | D | — | — | |
| 3 | Derivative | Class B Common Stock | 2023-07-20 | C | D | 10,000 | $0.00 | 6,531,496 | D | $0.00 · — to — | 10,000 Class A Common Stock | (F6) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |